All content for All Things Urticaria is the property of Global Allergy and Asthma Excellence Network - UCARE in collaboration with Medthority and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professor Marcus Maurer and Professor Martin Metz reflect on the European Academy of Allergy and Clinical Immunology (EAACI) congress 2024, including novel treatments on the horizon, key takeaways and expectations for future meetings.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: Remibrutinib demonstrates favourable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks; andEuropean Medicines Agency approved indications for omalizumab biosimilar.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 100 will be held live on UDAY (1 October 2024, 14:30 CEST). Submit your questions in advance to info@ga2len-ucare.com.
Follow UCARE on Instagram to be notified of more information https://www.instagram.com/ga2len_acare_ucare/.
